Your browser doesn't support javascript.
loading
Follow-up of immune response in patients with common variable immunodeficiency following SARS-CoV-2 vaccination.
Gutiérrez-Bautista, Juan Francisco; Díaz-Alberola, Irene; Tarriño, María; Aguilera, María; Cobo, Fernando; Reguera, Juan Antonio; Rodríguez-Granger, Javier; Mendoza, Joaquín; López-Nevot, Miguel Ángel; Sampedro, Antonio.
Affiliation
  • Gutiérrez-Bautista JF; Departamento de Bioquímica, Biología Molecular e Inmunología III, University of Granada, Granada, Spain.
  • Díaz-Alberola I; Servicio de Análisis Clínicos e Inmunología, University Hospital Virgen de las Nieves, Granada, Spain.
  • Tarriño M; Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, Spain.
  • Aguilera M; Servicio de Análisis Clínicos e Inmunología, University Hospital Virgen de las Nieves, Granada, Spain.
  • Cobo F; Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, Spain.
  • Reguera JA; Servicio de Microbiología, University Hospital Virgen de las Nieves, Granada, Spain.
  • Rodríguez-Granger J; Servicio de Microbiología, University Hospital Virgen de las Nieves, Granada, Spain.
  • Mendoza J; Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, Spain.
  • López-Nevot MÁ; Servicio de Microbiología, University Hospital Virgen de las Nieves, Granada, Spain.
  • Sampedro A; Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, Spain.
Clin Exp Immunol ; 217(3): 253-262, 2024 Aug 09.
Article in En | MEDLINE | ID: mdl-38693777
ABSTRACT
The COVID-19 pandemic highlighted the importance of effective vaccination strategies in controlling the spread of infectious diseases. SARS-CoV-2 vaccine has demonstrated high efficacy in preventing COVID-19 infection in the general population. However, the efficacy of this vaccine in patients with predominantly antibody deficiencies, such as common variable immunodeficiency (CVID) and X-linked agammaglobulinemia (XLA), should be closely monitored. CVID and XLA are rare genetic disorders that impair the immune system's ability to produce antibodies, which are crucial for fighting infections. Patients with these disorders have a higher risk of severe disease and mortality from COVID-19 due to their compromised immune systems. In this study, we evaluated the humoral and cellular immune responses after four doses of mRNA-1273 and one BNT162b2 bivalent vaccine in a cohort of patients with CVID and XLA. The response in this population was lower than in the control group. However, the administration of the third dose improved the number of patients with seroconversion and the intensity of the humoral response, as well as the number of patients with a positive cellular response. Finally, the administration of the fourth and fifth doses improves the antibody titer and neutralization against wild type variant, but not against the prevalent XBB1.5 variant.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Vaccination / Common Variable Immunodeficiency / Agammaglobulinemia / SARS-CoV-2 / COVID-19 / BNT162 Vaccine / Antibodies, Viral Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: Clin Exp Immunol Year: 2024 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Vaccination / Common Variable Immunodeficiency / Agammaglobulinemia / SARS-CoV-2 / COVID-19 / BNT162 Vaccine / Antibodies, Viral Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: Clin Exp Immunol Year: 2024 Document type: Article Affiliation country: